Shlomo Melmed

Summary

Affiliation: Cedars-Sinai Medical Center
Country: USA

Publications

  1. ncbi Pituitary magnetic resonance imaging for sellar and parasellar masses: ten-year experience in 2598 patients
    Pouyan Famini
    Departments of Medicine, Cedars Sinai Medical Center, 8700 Beverly Boulevard, Room 2015, Los Angeles, California 90048, USA
    J Clin Endocrinol Metab 96:1633-41. 2011
  2. ncbi Prospective safety surveillance of GH-deficient adults: comparison of GH-treated vs untreated patients
    Mark L Hartman
    Lilly Research Laboratories, Indianapolis, Indiana 46285, USA
    J Clin Endocrinol Metab 98:980-8. 2013
  3. ncbi Estradiol partially recapitulates murine pituitary cell cycle response to pregnancy
    Yoel Toledano
    Department of Medicine, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
    Endocrinology 153:5011-22. 2012
  4. ncbi Mechanisms for pituitary tumorigenesis: the plastic pituitary
    Shlomo Melmed
    Cedars Sinai Medical Center, David Geffen School of Medicine, University of California, 8700 Beverly Boulevard, Room 2015, Los Angeles, California 90048, USA
    J Clin Invest 112:1603-18. 2003
  5. ncbi Guidelines for acromegaly management
    S Melmed
    Cedars-Sinai Research Institute-UCLA School of Medicine, Los Angeles, California 90048, USA
    J Clin Endocrinol Metab 87:4054-8. 2002
  6. ncbi Discordant proliferation and differentiation in pituitary tumor-transforming gene-null bone marrow stem cells
    Tami Rubinek
    Academic Affairs, Rm 2015, Cedars Sinai Medical Center, 8700 Beverly Blvd, Los Angeles, CA 90048, USA
    Am J Physiol Cell Physiol 293:C1082-92. 2007
  7. ncbi Pathogenesis of pituitary tumors
    Shlomo Melmed
    Cedars Sinai Medical Center, Academic Affairs Room 2015, 8700 Beverly Boulevard, Los Angeles, CA 90048, USA
    Nat Rev Endocrinol 7:257-66. 2011
  8. ncbi A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly
    Shlomo Melmed
    Department of Medicine, Cedars Sinai Research Institute, David Geffen School of Medicine, University of California, Los Angeles, California 90048, USA
    J Clin Endocrinol Metab 90:4405-10. 2005
  9. ncbi Acromegaly pathogenesis and treatment
    Shlomo Melmed
    Department of Medicine, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
    J Clin Invest 119:3189-202. 2009
  10. ncbi Rat prolactinoma cell growth regulation by epidermal growth factor receptor ligands
    George Vlotides
    Department of Medicine, Cedars Sinai Medical Center, University of California School of Medicine, Los Angeles, California 90048, USA
    Cancer Res 68:6377-86. 2008

Collaborators

Detail Information

Publications91

  1. ncbi Pituitary magnetic resonance imaging for sellar and parasellar masses: ten-year experience in 2598 patients
    Pouyan Famini
    Departments of Medicine, Cedars Sinai Medical Center, 8700 Beverly Boulevard, Room 2015, Los Angeles, California 90048, USA
    J Clin Endocrinol Metab 96:1633-41. 2011
    ..Although pituitary adenomas are the most frequently encountered sellar mass lesions, other etiologies should be considered in the differential diagnosis of a sellar mass...
  2. ncbi Prospective safety surveillance of GH-deficient adults: comparison of GH-treated vs untreated patients
    Mark L Hartman
    Lilly Research Laboratories, Indianapolis, Indiana 46285, USA
    J Clin Endocrinol Metab 98:980-8. 2013
    ..In clinical practice, the safety profile of GH replacement therapy for GH-deficient adults compared with no replacement therapy is unknown...
  3. ncbi Estradiol partially recapitulates murine pituitary cell cycle response to pregnancy
    Yoel Toledano
    Department of Medicine, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
    Endocrinology 153:5011-22. 2012
    ..Murine pituitary meets the demand for prolactin during lactation associated with induction of both cell proliferative and inhibitory pathways, mediated, at least partially, by estradiol...
  4. ncbi Mechanisms for pituitary tumorigenesis: the plastic pituitary
    Shlomo Melmed
    Cedars Sinai Medical Center, David Geffen School of Medicine, University of California, 8700 Beverly Boulevard, Room 2015, Los Angeles, California 90048, USA
    J Clin Invest 112:1603-18. 2003
    ....
  5. ncbi Guidelines for acromegaly management
    S Melmed
    Cedars-Sinai Research Institute-UCLA School of Medicine, Los Angeles, California 90048, USA
    J Clin Endocrinol Metab 87:4054-8. 2002
  6. ncbi Discordant proliferation and differentiation in pituitary tumor-transforming gene-null bone marrow stem cells
    Tami Rubinek
    Academic Affairs, Rm 2015, Cedars Sinai Medical Center, 8700 Beverly Blvd, Los Angeles, CA 90048, USA
    Am J Physiol Cell Physiol 293:C1082-92. 2007
    ..The results indicate that Pttg deletion reduces BMSC proliferation, renders cells more sensitive to hypoxia, and enhances senescent features, thus pointing to a role for Pttg in the maintenance and proliferation of BMSCs...
  7. ncbi Pathogenesis of pituitary tumors
    Shlomo Melmed
    Cedars Sinai Medical Center, Academic Affairs Room 2015, 8700 Beverly Boulevard, Los Angeles, CA 90048, USA
    Nat Rev Endocrinol 7:257-66. 2011
    ..Understanding subcellular mechanisms that underlie pituitary tumorigenesis will enable development of tumor aggression markers as well as novel targeted therapies...
  8. ncbi A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly
    Shlomo Melmed
    Department of Medicine, Cedars Sinai Research Institute, David Geffen School of Medicine, University of California, Los Angeles, California 90048, USA
    J Clin Endocrinol Metab 90:4405-10. 2005
    ....
  9. ncbi Acromegaly pathogenesis and treatment
    Shlomo Melmed
    Department of Medicine, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
    J Clin Invest 119:3189-202. 2009
    ..Effective control of GH and IGF1 hypersecretion and ablation or stabilization of the pituitary tumor mass lead to improved comorbidities and lowering of mortality rates for this hormonal disorder...
  10. ncbi Rat prolactinoma cell growth regulation by epidermal growth factor receptor ligands
    George Vlotides
    Department of Medicine, Cedars Sinai Medical Center, University of California School of Medicine, Los Angeles, California 90048, USA
    Cancer Res 68:6377-86. 2008
    ..EGFR inhibitors could therefore be useful for the control of PRL secretion and tumor load in prolactinomas resistant to dopaminergic treatment, or for those prolactinomas undergoing rare malignant transformation...
  11. ncbi Senescence mediates pituitary hypoplasia and restrains pituitary tumor growth
    Vera Chesnokova
    Department of Medicine, Cedars Sinai Medical Center, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA 90048, USA
    Cancer Res 67:10564-72. 2007
    ....
  12. ncbi p21(Cip1) restrains pituitary tumor growth
    Vera Chesnokova
    Department of Medicine, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
    Proc Natl Acad Sci U S A 105:17498-503. 2008
    ..Aneuploid pituitary cell p21 may constrain pituitary tumor growth, thus accounting for the very low incidence of pituitary carcinomas...
  13. ncbi Lineage-specific restraint of pituitary gonadotroph cell adenoma growth
    Vera Chesnokova
    Department of Medicine, Pituitary Center, Cedars Sinai Medical Center, Los Angeles, California, United States of America
    PLoS ONE 6:e17924. 2011
    ..These results point to lineage-specific pathways restricting uncontrolled murine and human pituitary gonadotroph adenoma cell growth...
  14. ncbi E2F1 induces pituitary tumor transforming gene (PTTG1) expression in human pituitary tumors
    Cuiqi Zhou
    Department of Medicine, Cedars Sinai Medical Center, David Geffen School of Medicine at UCLA, Los Angeles, California 90048, USA
    Mol Endocrinol 23:2000-12. 2009
    ..These results elucidate a mechanism for abundant tumor hPTTG1 expression, whereby Rb inactivation releases E2F1 to induce hPTTG1. This signaling pathway may underlie the requirement of PTTG1 for pituitary tumorigenesis...
  15. ncbi Regulation of growth hormone and prolactin gene expression and secretion by chimeric somatostatin-dopamine molecules
    Anna Gruszka
    Division of Endocrinology, Cedars Sinai Research Institute, University of California School of Medicine, 8700 Beverly Boulevard, Los Angeles, CA 90048, USA
    Endocrinology 148:6107-14. 2007
    ..The results show that SRIF analogs and SRIF/DA molecules inhibit GH and PRL secretion and suppress PRL but not GH gene expression...
  16. ncbi Suppression of rat and human growth hormone and prolactin secretion by a novel somatostatin/dopaminergic chimeric ligand
    Song-Guang Ren
    Cedars-Sinai Research Institute, University of California School of Medicine, Los Angeles, California 90048, USA
    J Clin Endocrinol Metab 88:5414-21. 2003
    ..The SRIF/DA chimeric molecule, BIM-23A387, represents a novel tool for effective drug treatment of acromegaly and for prolactinomas otherwise resistant to dopaminergic therapy...
  17. ncbi Heregulin regulates prolactinoma gene expression
    George Vlotides
    Department of Medicine, Cedars Sinai Medical Center, University of California School of Medicine, Los Angeles, CA, USA
    Cancer Res 69:4209-16. 2009
    ..Targeted inhibition of up-regulated p185(c-neu)/ErbB3 activity could be useful for the treatment of aggressive prolactinomas resistant to conventional therapy...
  18. ncbi Differential ligand-mediated pituitary somatostatin receptor subtype signaling: implications for corticotroph tumor therapy
    Anat Ben-Shlomo
    Department of Medicine, Pituitary Center, Cedars SinaiMedical Center, Los Angeles, California 90048, USA
    J Clin Endocrinol Metab 94:4342-50. 2009
    ..However, there is no direct evidence for this assumption, and moreover, the ligand effect on corticotroph SST2 is not known...
  19. ncbi Central and peripheral actions of somatostatin on the growth hormone-IGF-I axis
    Robert D Murray
    Department of Medicine, Cedars Sinai Research Institute, UCLA School of Medicine, Los Angeles, California 90048, USA
    J Clin Invest 114:349-56. 2004
    ..The results demonstrate that SRIF acts both centrally and peripherally to control the GH-IGF-I axis, providing a mechanistic explanation for SRIF analog action in treating patients with GH-secreting pituitary adenomas...
  20. ncbi Leukemia inhibitory factor regulates prolactin secretion in prolactinoma and lactotroph cells
    Anat Ben-Shlomo
    Division of Endocrinology and Metabolism, Cedars Sinai Research Institute, University of California School of Medicine, Los Angeles, California 90048, USA
    J Clin Endocrinol Metab 88:858-63. 2003
    ..These observations indicate a role for LIF in loss of autocrine PRL suppression contributing to unrestrained prolactinomas PRL secretion. Moreover, PRL suppression by LIF may be mediated by gp130 and D2R interaction...
  21. ncbi CEBPD suppresses prolactin expression and prolactinoma cell proliferation
    Yunguang Tong
    Academic Affairs, Los Angeles, California 90048, USA
    Mol Endocrinol 25:1880-91. 2011
    ..CEBPD also suppresses expression of proliferation-related genes, including c-Myc, survivin, as well as cyclins B1, B2, and D1. These results show that PRL expression and cell proliferation are controlled in part by CEBPD...
  22. ncbi Murine pituitary tumor-transforming gene functions as a securin protein in insulin-secreting cells
    Run Yu
    UCLA School of Medicine, Cedars Sinai Research Institute, Cedars Sinai Medical Center, 8700 Beverly Blvd, Room D3066, Los Angeles, California 90048, USA
    J Endocrinol 191:45-53. 2006
    ....
  23. ncbi In vivo time-lapse imaging delineates the zebrafish pituitary proopiomelanocortin lineage boundary regulated by FGF3 signal
    Ning Ai Liu
    Department of Medicine, Cedars Sinai Research Institute, University of California Los Angeles, Los Angeles, California 90048, USA
    Dev Biol 319:192-200. 2008
    ....
  24. ncbi Constitutive somatostatin receptor activity determines tonic pituitary cell response
    Anat Ben-Shlomo
    Cedars Sinai Medical Center, 8700 Beverly Boulevard, Academic Affairs, Room 2015, Los Angeles, California 90048, USA
    Mol Endocrinol 23:337-48. 2009
    ..Thus, integrated pituitary cell ACTH regulation is determined both by phasic SRIF action, as well as by tonic constitutive SST activity, independently of SRIF...
  25. ncbi Pituitary hypoplasia in Pttg-/- mice is protective for Rb+/- pituitary tumorigenesis
    Vera Chesnokova
    Cedars Sinai Research Institute, David Geffen School of Medicine at UCLA, Los Angeles, California 90048, USA
    Mol Endocrinol 19:2371-9. 2005
    ..01). Pituitary hypoplasia, associated with suppressed cell proliferation, prevents the high penetrance of pituitary tumors in Rb+/- animals, and is therefore a protective determinant for pituitary tumorigenesis...
  26. ncbi PTTG1 attenuates drug-induced cellular senescence
    Yunguang Tong
    Department of Medicine, Cedars Sinai Medical Center, University of California Los Angeles, Los Angeles, California, United States of America
    PLoS ONE 6:e23754. 2011
    ..As senescence is a determinant of cell responses to anti-neoplastic treatments, these findings suggest PTTG1 as a tumor cell marker to predict anti-neoplastic treatment outcomes...
  27. ncbi PPAR-gamma receptor ligands: novel therapy for pituitary adenomas
    Anthony P Heaney
    Cedars Sinai Research Institute, University of California Los Angeles School of Medicine, Los Angeles, California 90048, USA
    J Clin Invest 111:1381-8. 2003
    ..TZDs are proposed as novel oral medications for managing pituitary tumors...
  28. ncbi Targeting zebrafish and murine pituitary corticotroph tumors with a cyclin-dependent kinase (CDK) inhibitor
    Ning Ai Liu
    Department of Medicine, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Proc Natl Acad Sci U S A 108:8414-9. 2011
    ..The results suggest that use of selective CDK inhibitors could effectively target corticotroph tumor growth and hormone secretion...
  29. ncbi Human pituitary tumor-transforming gene (PTTG1) motif suppresses prolactin expression
    Gregory A Horwitz
    Cedars Sinai Medical Center, 8700 Beverly Boulevard, Room 2015, Los Angeles, California 90048, USA
    Mol Endocrinol 17:600-9. 2003
    ..These results indicate that targeting PTTG1-mediated signaling alters the hormonal phenotype in pituitary cells and disrupted PTTG1 action may be a potential subcellular therapeutic tool for repressing PRL hypersecretion...
  30. ncbi Oct-1 induces pituitary tumor transforming gene expression in endocrine tumors
    Cuiqi Zhou
    Department of Medicine Pathology, David Geffen School of Medicine at UCLA, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
    Endocr Relat Cancer 15:817-31. 2008
    ..05) respectively. The results show that Oct-1 transactivates hPTTG1, and both proteins are concordantly overexpressed in endocrine tumors, thus offering a mechanism for endocrine tumor hPTTG1 abundance...
  31. ncbi Selective regulation of somatostatin receptor subtype signaling: evidence for constitutive receptor activation
    Anat Ben-Shlomo
    Department of Medicine, Cedars Sinai Research Institute, David Geffen School of Medicine at UCLA, Los Angeles, California 90048, USA
    Mol Endocrinol 21:2565-78. 2007
    ....
  32. ncbi EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomas
    Hidenori Fukuoka
    Pituitary Center, Department of Medicine, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
    J Clin Invest 121:4712-21. 2011
    ..These results indicate that inhibiting EGFR signaling may be a novel strategy for treating Cushing disease...
  33. ncbi Pituitary tumor transforming gene overexpression facilitates pituitary tumor development
    Ines Donangelo
    Department of Medicine, Cedars Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, California 90048, USA
    Endocrinology 147:4781-91. 2006
    ....
  34. ncbi Pyridoxal phosphate inhibits pituitary cell proliferation and hormone secretion
    Song-Guang Ren
    Department of Medicine, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Room 2015, Los Angeles, California 90048, USA
    Endocrinology 147:3936-42. 2006
    ..Pyridoxine may therefore be appropriate for testing as a relatively safe drug for adjuvant treatment of hormone-secreting pituitary adenomas...
  35. ncbi Pituitary tumour-transforming gene (PTTG) and pituitary senescence
    Vera Chesnokova
    Cedars Sinai Medical Center, David Geffen School of Medicine, Los Angeles, CA 90048, USA
    Horm Res 71:82-7. 2009
    ..These results improve our understanding of pituitary syndromes associated with infertility, growth disorders, hypercortisolism or adrenal, thyroid and gonadal failure due to abrogated pituitary function...
  36. ncbi Pituitary senescence: the evolving role of Pttg
    Vera Chesnokova
    Department of Medicine, Division of Endocrinology and Metabolism, Cedars Sinai Medical Center David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA 90048, USA
    Mol Cell Endocrinol 326:55-9. 2010
    ..These observations point to senescence as a target for effective therapy for both tumor silencing and growth restraint towards development of pituitary malignancy...
  37. ncbi Cell-specific pituitary gene expression profiles after treatment with leukemia inhibitory factor reveal novel modulators for proopiomelanocortin expression
    Rula A Abbud
    Division of Endocrinology, Department of Medicine, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Endocrinology 145:867-80. 2004
    ..Thus, using GeneChips, C/EBPbeta and GIF have been identified as novel mediators and AHSG/fetuin as an inhibitor of LIF action in corticotropes...
  38. ncbi Prolactin receptor signaling mediates the osmotic response of embryonic zebrafish lactotrophs
    Ning Ai Liu
    Department of Medicine, Cedars Sinai Research Institute, University of California, Los Angeles, California 90048, USA
    Mol Endocrinol 20:871-80. 2006
    ....
  39. ncbi The novel somatostatin ligand (SOM230) regulates human and rat anterior pituitary hormone secretion
    Robert D Murray
    Cedars-Sinai Research Institute, University of California Los Angeles School of Medicine, Los Angeles, California 90048, USA
    J Clin Endocrinol Metab 89:3027-32. 2004
    ..As a consequence of its broader binding profile, SOM230 is likely to find clinical utility in treating tumors resistant to SSTR-2-preferential analogs...
  40. ncbi Somatostatin agonists for treatment of acromegaly
    Anat Ben-Shlomo
    Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Mol Cell Endocrinol 286:192-8. 2008
    ..Disease control is evaluated by biochemical markers, tumor shrinkage, and disease-symptom improvement balanced against drug-related side effects...
  41. ncbi Somatostatin analogs and chimeric somatostatin-dopamine molecules differentially regulate human growth hormone and prolactin gene expression and secretion in vitro
    Anna Gruszka
    Division of Endocrinology, Cedars Sinai Research Institute, University of California School of Medicine, Los Angeles, CA 90048, USA
    Mol Cell Endocrinol 362:104-9. 2012
    ..SRIF/DA and BIM-53097 inhibit both PRL secretion and PRL gene expression. SST5 agonist inhibits PRL secretion, but does not suppress PRL gene expression. D(2) affinity is crucial in SRIF/DA action on PRL gene expression...
  42. ncbi Functional PPAR-gamma receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas
    Anthony P Heaney
    Department of Medicine, Cedars Sinai Research Institute, University of California Los Angeles School of Medicine, Los Angeles, California, USA
    Nat Med 8:1281-7. 2002
    ..Based on these findings, thiazolidinediones may be an effective therapy for Cushing disease..
  43. ncbi HER2/ErbB2 receptor signaling in rat and human prolactinoma cells: strategy for targeted prolactinoma therapy
    Hidenori Fukuoka
    Cedars Sinai Medical Center, Department of Academic Affairs, 8700 Beverly Boulevard Plaza North, Los Angeles, CA 90048, USA
    Mol Endocrinol 25:92-103. 2011
    ..Because pituitary HER2 signaling is abrogated by TKIs, this receptor could be an effective target for prolactinoma therapy...
  44. ncbi Molecular mechanisms of pituitary adenoma senescence
    Vera Chesnokova
    Department of Medicine, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Front Horm Res 38:7-14. 2010
    ..In this review we highlight an intrinsic predisposition of pituitary tumors to exhibit senescence-associated molecular pathways and show prospective mechanisms underlying the benign nature of these commonly encountered tumors...
  45. ncbi A novel molecular marker of pituitary tumor transforming gene involves in a rat liver regeneration
    Kozo Akino
    Department of Medicine, Cedars-Sinai Research Institute UCLA School of Medicine, Los Angeles, California, USA
    J Surg Res 129:142-6. 2005
    ....
  46. ncbi Somatostatin receptor type 5 modulates somatostatin receptor type 2 regulation of adrenocorticotropin secretion
    Anat Ben-Shlomo
    Department of Medicine, Cedars Sinai Research Institute, David Geffen School of Medicine, UCLA, Los Angeles, California 90048, USA
    J Biol Chem 280:24011-21. 2005
    ..This may explain superior somatostatin-28 potency and provides a rationale for somatostatin ligand design to treat ACTH-secreting pituitary tumors...
  47. ncbi Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide Autogel therapy: a randomized, placebo-controlled, multicenter study with a 52 week open extension
    Shlomo Melmed
    Department of Medicine, Cedars Sinai Medical Center, Los Angeles, CA, USA
    Pituitary 13:18-28. 2010
    ..Treatment was well tolerated by all patients. In conclusion, Lan-Autogel was effective in controlling GH and IGF-1 hypersecretion in patients with acromegaly and showed a rapid onset of action...
  48. ncbi Medical progress: Acromegaly
    Shlomo Melmed
    Department of Medicine, Cedars-Sinai Medical Center, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles 90048, USA
    N Engl J Med 355:2558-73. 2006
  49. ncbi Genomic characterization of human and rat prolactinomas
    Yunguang Tong
    Department of Medicine, Cedars Sinai Medical Center, Academic Affairs, Room 2015, 8700 Beverly Boulevard, Los Angeles, California 90048, USA
    Endocrinology 153:3679-91. 2012
    ..In summary, characterization of individual genes and gene sets in human and in estrogen-induced rat prolactinomas validates the model and provides insights into genomic changes associated with this commonly encountered pituitary tumor...
  50. ncbi Clusterin and FOXL2 act concordantly to regulate pituitary gonadotroph adenoma growth
    Vera Chesnokova
    Pituitary Center, Department of Medicine, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
    Mol Endocrinol 26:2092-103. 2012
    ..Thus, gonadotroph tumor cell proliferation is determined by the interplay between cell-specific FOXL2 with PTTG and Clu...
  51. ncbi The utility of oral glucose tolerance testing for diagnosis and assessment of treatment outcomes in 166 patients with acromegaly
    John D Carmichael
    Department of Medicine, Research Institute, Cedars Sinai Medical Center, 8700 Beverly Boulevard, Room 2015, Los Angeles, California 90048, USA
    J Clin Endocrinol Metab 94:523-7. 2009
    ..The OGTT is the gold standard for determining control of GH secretion at diagnosis and after surgical treatment, but the usefulness of performing an OGTT in patients treated with medical therapy has not been determined...
  52. ncbi Lipodystrophy in patients with acromegaly receiving pegvisomant
    Vivien S Bonert
    Department of Medicine, Cedars Sinai Medical Center, David Geffen School of Medicine at University of California, Los Angeles, California 90048, USA
    J Clin Endocrinol Metab 93:3515-8. 2008
    ..Documented side effects in the initial registration studies included headache, injection-site reactions, flu-like syndrome, and reversible elevation of hepatic enzymes...
  53. ncbi Early multipotential pituitary focal hyperplasia in the alpha-subunit of glycoprotein hormone-driven pituitary tumor-transforming gene transgenic mice
    Rula A Abbud
    Department of Medicine, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, CA 90048, USA
    Mol Endocrinol 19:1383-91. 2005
    ..These results provide evidence for early pituitary plasticity, whereby PTTG overexpression results in a phenotype switch in early pituitary stem cells and promotes differentiated polyhormonal cell focal expansion...
  54. ncbi Current status and future opportunities for controlling acromegaly
    Shlomo Melmed
    Division of Endocrinology and Metabolism, Ceder Sinai Medical Center, Los Angeles, CA 90048, USA
    Pituitary 5:185-96. 2002
    ..Early studies have reported IGF-I normalization in 48% of lanreotide-treated patients and up to 97% of pegvisomant-treated...
  55. ncbi Molecular targets in pituitary tumours
    Anthony P Heaney
    Cedars-Sinai Research Institute, 8700 Beverly Blvd, Geffen School of Medicine at UCLA, Los Angeles, California 90048, USA
    Nat Rev Cancer 4:285-95. 2004
  56. ncbi Clinical review 154: The role of pharmacotherapy in perioperative management of patients with acromegaly
    Anat Ben-Shlomo
    Cedars-Sinai Research Institute, University of California Los Angeles School of Medicine, Los Angeles, California 90048, USA
    J Clin Endocrinol Metab 88:963-8. 2003
  57. ncbi Aryl hydrocarbon receptor interacting protein variants in sporadic pituitary adenomas
    Run Yu
    Cedars Sinai Medical Center, 8700 Beverly Boulevard, Room 2015, Los Angeles, California 90048, USA
    J Clin Endocrinol Metab 91:5126-9. 2006
    ....
  58. ncbi Pituitary tumor transforming gene: an update
    Run Yu
    Cedars Sinai Research Institute, UCLA School of Medicine, Los Angeles, CA 90048, USA
    Front Horm Res 32:175-85. 2004
    ....
  59. ncbi Expression and function of ErbB receptors and ligands in the pituitary
    Odelia Cooper
    Department of Medicine, Pituitary Center, Cedars Sinai Medical Center, Academic Affairs, Room 2015, 8700 Beverly Boulevard, Los Angeles, California 90048, USA
    Endocr Relat Cancer 18:R197-211. 2011
    ..ErbB tyrosine kinase inhibitors regulate hormonal secretion, cell morphology, and proliferation in lacto-somatotroph tumors, reflecting the emerging application of targeted pituitary therapeutics...
  60. ncbi Overexpressed pituitary tumor-transforming gene causes aneuploidy in live human cells
    Run Yu
    Cedars Sinai Research Institute, Universityof California Los Angeles School of Medicine, 90048, USA
    Endocrinology 144:4991-8. 2003
    ..These results demonstrate that PTTG induces aneuploidy in single, live, human cancer cells...
  61. ncbi Functional association of somatostatin receptor subtypes 2 and 5 in inhibiting human growth hormone secretion
    Song-Guang Ren
    Cedars-Sinai Research Institute, University of California, Los Angeles, School of Medicine, Los Angeles, California 90048, USA
    J Clin Endocrinol Metab 88:4239-45. 2003
    ....
  62. ncbi Silent corticogonadotroph adenomas: clinical and cellular characteristics and long-term outcomes
    Odelia Cooper
    Pituitary Center, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Horm Cancer 1:80-92. 2010
    ..As SCAs exhibit features consistent with both corticotroph and gonadotroph cytologic origin, we propose a pathologic and clinically distinct classification of SCAs as silent corticogonadotroph adenomas...
  63. ncbi Fibroblast growth factor-2 autofeedback regulation in pituitary folliculostellate TtT/GF cells
    George Vlotides
    Department of Medicine, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
    Endocrinology 150:3252-8. 2009
    ....
  64. ncbi Pituitary tumor transforming gene-null male mice exhibit impaired pancreatic beta cell proliferation and diabetes
    Zhiyong Wang
    Department of Medicine, Cedars Sinai Research Institute, University of California School of Medicine, Los Angeles, CA 90048, USA
    Proc Natl Acad Sci U S A 100:3428-32. 2003
    ..PTTG-/- beta cells had pleiotropic nuclei, suggesting defects in cell division. The results indicated that securin is indispensable for normal pancreatic beta cell proliferation...
  65. ncbi Minireview: Neuro-immuno-endocrine modulation of the hypothalamic-pituitary-adrenal (HPA) axis by gp130 signaling molecules
    Vera Chesnokova
    Cedars-Sinai Research Institute, University of California-Los Angeles School of Medicine, 8700 Beverly Boulevard, Los Angeles, CA 90048, USA
    Endocrinology 143:1571-4. 2002
    ..At the same time, gp130 cytokines stimulate pituitary suppressor of cytokine signaling (SOCS)-3, which represses cytokine signaling and abrogates cytokine-induced corticotroph POMC gene transcription and ACTH secretion...
  66. ncbi Implication of pituitary tropic status on tumor development
    Ines Donangelo
    Cedars-Sinai Research Institute, UCLA School of Medicine, 8700 Beverly Boulevard, Los Angeles, CA 90048, USA
    Front Horm Res 35:1-8. 2006
    ..Understanding the mechanisms underlying changes in pituitary plasticity and their relationship to tumor development may contribute to the ability of regulating the development and progression of pituitary tumors...
  67. ncbi Acromegaly
    Anat Ben-Shlomo
    Cedars Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, CA, 90048, USA
    Endocrinol Metab Clin North Am 37:101-22, viii. 2008
    ..Pharmacologic treatments, including long-acting somatostatin analogs, dopamine agonists, and growth hormone receptor antagonists, have assumed more importance in achieving biochemical and symptomatic disease control...
  68. ncbi Anti-aging therapy with human growth hormone associated with metastatic colon cancer in a patient with Crohn's colitis
    Gil Y Melmed
    Department of Medicine, Cedars Sinai Medical Center, David Geffen School of Medicine, University of California, Los Angeles, California 90048, USA
    Clin Gastroenterol Hepatol 6:360-3. 2008
    ..The nonapproved use of human growth hormone (HGH) for anti-aging has been increasing. Theoretical concerns for neoplastic potentiation by HGH have been raised, but not proven clinically...
  69. ncbi Update in pituitary disease
    Shlomo Melmed
    Cedars Sinai Medical Center David Geffen UCLA School of Medicine, Los Angeles, California 90048, USA
    J Clin Endocrinol Metab 93:331-8. 2008
    ..Notably, they open up new vistas for creative scholarship in unraveling the challenges of pituitary medicine...
  70. ncbi Pituitary tumor-transforming gene: physiology and implications for tumorigenesis
    George Vlotides
    Department of Medicine, Cedars Sinai Medical Center, University of California School of Medicine, Los Angeles, California 90048, USA
    Endocr Rev 28:165-86. 2007
    ..Recent knowledge gained from PTTG1-null mouse models and transgenic animals and their potential application to subcellular therapeutic targeting PTTG1 are discussed...
  71. ncbi Treatment of acromegaly: future
    Ines Donangelo
    Cedars-Sinai Research Institute, UCLA David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California, USA
    Endocrine 28:123-8. 2005
    ..Careful individualization of therapy is important in deciding the ideal treatment approach, and primary medical therapy may be recommended in selected patients...
  72. ncbi Functional role of estrogen in pituitary tumor pathogenesis
    Anthony P Heaney
    Cedars Sinai Research Institute, University of California Los Angeles School of Medicine, Los Angeles, California, USA
    J Clin Invest 109:277-83. 2002
    ....
  73. ncbi Pituitary corticotroph ontogeny and regulation in transgenic zebrafish
    Ning-Ai Liu
    Department of Medicine, Cedars-Sinai Research Institute, University of California Los Angeles School of Medicine, 90048, USA
    Mol Endocrinol 17:959-66. 2003
    ..Transgenic zebrafish with specific POMC-GFP expression in pituitary corticotrophs offers a powerful genetic system for in vivo study of vertebrate corticotroph lineage development...
  74. ncbi Skin manifestations in acromegaly
    Anat Ben-Shlomo
    Department of Medicine, Cedars Sinai Research Institute, David Geffen School of Medicine at UCLA, Los Angeles, CA 90048, USA
    Clin Dermatol 24:256-9. 2006
    ..Discerning these changes contributes to early diagnosis and treatment of this high-morbidity disorder. Controlling GH and IGF-1 over-secretion alleviates most cutaneous manifestations of acromegaly; however, regression may be incomplete...
  75. ncbi Pasireotide--a somatostatin analog for the potential treatment of acromegaly, neuroendocrine tumors and Cushing's disease
    Anat Ben Shlomo
    Cedars Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, CA 90048, USA
    IDrugs 10:885-95. 2007
    ..The efficacy of pasireotide and any potential advantage over current therapies will need to be tested or validated in larger phase III clinical trials...
  76. ncbi Pathogenesis of pituitary tumors
    Run Yu
    Department of Medicine, Cedars Sinai Medical Center, Los Angeles, CA, USA
    Prog Brain Res 182:207-27. 2010
    ....
  77. ncbi Opposing effects of pituitary leukemia inhibitory factor and SOCS-3 on the ACTH axis response to inflammation
    Vera Chesnokova
    Cedars Sinai Research Institute University of California Los Angeles School of Medicine, Los Angeles, California 90048, USA
    Am J Physiol Endocrinol Metab 282:E1110-8. 2002
    ..05). The results indicate that, although LIF induces ACTH, SOCS-3 acts to counterregulate the HPA axis response to inflammation...
  78. ncbi Acromegaly with moderate hyperprolactinemia caused by an intrasellar macroadenoma
    Vivien S Bonert
    Cedars Sinai Medical Center, Los Angeles, CA, USA
    Nat Clin Pract Endocrinol Metab 2:408-12; quiz following 412. 2006
    ..DIAGNOSIS: Acromegaly and hyperprolactinemia caused by a mixed-cell adenoma, secreting growth hormone and prolactin. MANAGEMENT: Trans-sphenoidal surgery followed by medical therapy with 20 mg intramuscular octreotide-LAR monthly...
  79. ncbi Expression and function of pituitary tumour transforming gene for T-lymphocyte activation
    Rostyslav Stoika
    Division of Endocrinology, Cedars-Sinai Research Institute UCLA School of Medicine, Los Angeles, CA 90048, USA
    Br J Haematol 119:1070-4. 2002
    ..These results showed that PTTG-1 expression follows cell cycling patterns in T lymphocytes, providing a convenient model for studying PTTG functions in normal cells...
  80. ncbi Ovarian hyperstimulation syndrome caused by an FSH-secreting pituitary adenoma
    Odelia Cooper
    Cedars Sinai Medical Center, 8700 Beverly Boulevard, Room 2015, Los Angeles, CA 90048, USA
    Nat Clin Pract Endocrinol Metab 4:234-8. 2008
    ..A 40-year-old woman presented with galactorrhea and oligomenorrhea. She had a history of multiple ovarian cysts and pelvic pain...
  81. ncbi Body mass index determines evoked growth hormone (GH) responsiveness in normal healthy male subjects: diagnostic caveat for adult GH deficiency
    Vivien S Bonert
    Department of Medicine, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Room 2015, Los Angeles, CA 90048, USA
    J Clin Endocrinol Metab 89:3397-401. 2004
    ....
  82. ncbi Aryl hydrocarbon receptor interacting protein and pituitary tumorigenesis: another interesting protein
    Shlomo Melmed
    J Clin Endocrinol Metab 92:1617-9. 2007
  83. ncbi The cell adhesion molecules N-cadherin and neural cell adhesion molecule regulate human growth hormone: a novel mechanism for regulating pituitary hormone secretion
    Tami Rubinek
    Institute of Endocrinology, Chaim Sheba Medical Center, Tel-Hashomer 52621, Israel
    J Clin Endocrinol Metab 88:3724-30. 2003
    ..05). This study indicates that pituitary cell-cell contact mediated by homophilic interactions between adhesion molecules regulates human GH secretion...
  84. ncbi 2004 World Health Organization classification of pituitary tumors: what is new?
    Shlomo Melmed
    Acta Neuropathol 111:78-9. 2006
  85. ncbi Optimizing control of acromegaly: integrating a growth hormone receptor antagonist into the treatment algorithm
    David R Clemmons
    University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA
    J Clin Endocrinol Metab 88:4759-67. 2003
    ..Pegvisomant is the most effective drug treatment for acromegaly in normalizing IGF-I and producing a clinical response; it is the preferred agent in patients resistant to or intolerant of somatostatin analogs...
  86. ncbi Angiogenesis in endocrine tumors
    Helen E Turner
    Department of Endocrinology, Churchill Hospital, Oxford OX3 7LJ, United Kingdom
    Endocr Rev 24:600-32. 2003
    ..An understanding of the balance of angiogenesis in these vascular tumors and mechanisms of vascular control may assist in therapeutic decisions and allow appropriately targeted treatment...
  87. ncbi Acromegaly consensus: the next steps
    Andrea Giustina
    J Clin Endocrinol Metab 88:1913-4. 2003
  88. ncbi A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly
    Robert D Murray
    Department of Endocrinology, Leeds Teaching Hospitals National Health Service Trust, Leeds, UK
    J Clin Endocrinol Metab 93:2957-68. 2008
    ..A novel aqueous formulation of lanreotide, lanreotide Autogel (ATG), has recently been approved and is the predominant (and only in the United States) formulation of lanreotide used clinically...
  89. ncbi Elucidating the murine brain transcriptional network in a segregating mouse population to identify core functional modules for obesity and diabetes
    Pek Yee Lum
    Rosetta Inpharmatics, LLC, Merck and Co, Inc, Seattle, WA 98109, USA
    J Neurochem 97:50-62. 2006
    ..We identify core functional modules making up the brain transcriptional network in mice that are coherent for core biological processes associated with metabolic disease traits including obesity and diabetes...
  90. ncbi [Pituitary tumorigenesis]
    Marcello D Bronstein
    Departamento de Clinica Medica, Hospital das Clinicas, FMUSP, Sao Paulo, SP
    Arq Bras Endocrinol Metabol 49:615-25. 2005
    ..Several molecular mechanisms involved in pituitary tumorigenesis have been unraveled including oncogenes, tumor suppressor genes and growth factors involved in neoplastic development, and will be described in this review...
  91. ncbi The neuroprotective WldS gene regulates expression of PTTG1 and erythroid differentiation regulator 1-like gene in mice and human cells
    Thomas H Gillingwater
    Centre for Neuroscience Research, University of Edinburgh, 1 George Square, Edinburgh EH8 9JZ, UK
    Hum Mol Genet 15:625-35. 2006
    ..Targeting Wld(S)-induced gene expression may lead to novel therapies for neurodegeneration induced by trauma or by disease in humans...